R Sikorski - Concepedia

Author

R Sikorski

Also Known As

R S Sikorski, R Sikorski, R. S. Sikorski, R. Sikorski, R.S. Sikorski, ROBERTS. SIKORSKI, Roberts S Sikorski, Roberts. Sikorski

Publications

9.6K

Citations

H-Index

Concepts

All Affiliations

Johns Hopkins University Johns Hopkins Medicine

About

R Sikorski is an author at Johns Hopkins University specializing in medicine, cell biology, and molecular biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	739
2	Cell Biology	5	5	585
3	Natural Sciences	4	4	519
4	Engineering	1	1	36
5	Health Sciences	1	1	16

R Sikorski

Publications

9.5K

Citations

H-Index

Page 1

	Year	Citations
A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. R Sikorski, P. Hieter Genetics	1989	8.8K
Cdc16p, Cdc23p and Cdc27p form a complex essential for mitosis. John Lamb, William A. Michaud, R Sikorski, The EMBO Journal Cell RegulationCell DivisionComplex EssentialMedicineNatural Sciences	1994	242
Human p53 and CDC2Hs genes combine to inhibit the proliferation of Saccharomyces cerevisiae. Janice Nigro, R Sikorski, Steven I. Reed, Molecular and Cellular Biology Pronounced Growth InhibitionCell DeathMolecular BiologyCell ProliferationCell Cycle	1992	115
INDUCTION OF DNA‐PROTEIN CROSSLINKS IN HUMAN CELLS BY ULTRAVIOLET and VISIBLE RADIATIONS: ACTION SPECTRUM Jennifer G. Peak, Meyrick J. Peak, R Sikorski, Photochemistry and Photobiology Pyrimidine Dimer FormationPhotobiologyMolecular BiologyVisible RadiationsDna Spectrum	1985	101
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer George R. Blumenschein, Fairooz F. Kabbinavar, Hari Menon, Annals of Oncology Phase IiMedicinePathologyBronchial NeoplasmCancer Treatment	2011	90
A p21(Waf1/Cip1)carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Masato Mutoh, F.‐D. T. Lung, Yong-jie Long, PubMed ImmunologyCell DeathCellular PharmacologyW10 PeptideTumor Biology	1999	66
p62cdc23 of Saccharomyces cerevisiae: a nuclear tetratricopeptide repeat protein with two mutable domains. R Sikorski, William A. Michaud, Philip Hieter Molecular and Cellular Biology GeneticsCdc23 Gene ProductMolecular BiologyMolecular GeneticsCdc23 Point Mutant	1993	61
Expression of the Rickettsia prowazekii citrate synthase gene in Escherichia coli D O Wood, W H Atkinson, R Sikorski, Journal of Bacteriology BiosynthesisEngineeringVirulence FactorPathogenesisBacteriology	1983	36
Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC). G. R. Blumenschein, Fairooz F. Kabbinavar, Hari Menon, Journal of Clinical Oncology Motesanib BidCardiovascular PharmacologyPharmacotherapySmall Molecule AntagonistOncology	2010	16
Panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Effect of <i>KRAS</i> mutation status on second-line treatment (tx) with pmab and FOLFIRI Allen Lee Cohn, Deborah A. Smith, Marcus A. Neubauer, Journal of Clinical Oncology ImmunologyPathologySecond-line TreatmentOncologyGastrointestinal Oncology	2008	12

Page 1